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Heparins are present as cell surface glycosaminoglycans and have crucial regulatory roles in normal physiological processes and pathophysiological conditions, including tumor onset, proliferation, and metastasis \[[1](#onco12293-bib-0001){ref-type="ref"}\], \[[2](#onco12293-bib-0002){ref-type="ref"}\], \[[3](#onco12293-bib-0003){ref-type="ref"}\], \[[4](#onco12293-bib-0004){ref-type="ref"}\]. Possible antitumor effects of heparin include prevention of metastasis via inhibition of heparanase and interaction with P‐selectin \[[5](#onco12293-bib-0005){ref-type="ref"}\], \[[6](#onco12293-bib-0006){ref-type="ref"}\], \[[7](#onco12293-bib-0007){ref-type="ref"}\], \[[8](#onco12293-bib-0008){ref-type="ref"}\], \[[9](#onco12293-bib-0009){ref-type="ref"}\], \[[10](#onco12293-bib-0010){ref-type="ref"}\], \[[11](#onco12293-bib-0011){ref-type="ref"}\], \[[12](#onco12293-bib-0012){ref-type="ref"}\], \[[13](#onco12293-bib-0013){ref-type="ref"}\], \[[14](#onco12293-bib-0014){ref-type="ref"}\]. Heparin administration is limited by its anticoagulant effects. Necuparanib is a noncytotoxic, glycol‐split, heparan sulfate mimetic intended to treat advanced malignancies. Necuparanib is rationally engineered from heparin through a process that reduces anticoagulant activity while preserving activity against a number of heparin‐binding proteins involved in tumor progression and metastasis. \[[15](#onco12293-bib-0015){ref-type="ref"}\], \[[16](#onco12293-bib-0016){ref-type="ref"}\], \[[17](#onco12293-bib-0017){ref-type="ref"}\]

 {#onco12293-sec-9905}

imageJohn Wiley & Sons, Ltd.

imageJohn Wiley & Sons, Ltd.

 {#onco12293-sec-8905}

This is the first clinical evaluation of necuparanib, a novel therapeutic agent, which was conducted in patients with metastatic pancreatic adenocarcinoma. Necuparanib in combination with nab‐paclitaxel and gemcitabine demonstrated acceptable tolerability. No clear dose‐proportional trends in individual adverse events (AEs) were observed. The most common AEs had comparable rates, when necuparanib was administered with gemcitabine with or without nab‐paclitaxel, to what would be expected with chemotherapy alone. The grade 3/4 hematological toxicities observed in this study in the necuparanib + nab‐paclitaxel and gemcitabine cohort were similar to those observed in the Von Hoff phase III MPACT trial (neutropenia, 3% vs. 38%; anemia, 3% vs. 13%; and thrombocytopenia, 0% vs. 13%, respectively). No grade 3/4 AEs of leukocytosis, febrile neutropenia, epistaxis, pulmonary embolism, deep vein thrombosis, phlebitis, or hematuria were reported with the necuparanib + nab‐paclitaxel and gemcitabine regimen.

Based on collective safety and on PK, progressive disease (PD), biomarker, and efficacy data, a 5 mg/kg necuparanib dose, with capping at 450 mg, providing for a reasonable injection volume (i.e., two injections daily), was selected for further clinical evaluation in part B (randomized phase II trial). Pharmacodynamic data (i.e., hepatocyte growth factor) showed saturation with necuparanib 5 mg/kg and subtherapeutic levels of anticoagulation, which may be beneficial for thrombosis prevention. Promising antitumor activity was observed, as evidenced by survival and response data, with an overall disease‐control rate of 63% when all dose cohorts were pooled. Similarly, promising effects on reduction in Carbohydrate antigen 19‐9 (CA19.9) levels from baseline with necuparanib treatment were observed. The median overall survival for patients who received at least one dose (13.1 months) and at least one cycle (15.6 months) of necuparanib + nab*‐*paclitaxel + gemcitabine compared favorably with the phase III data for nab*‐*paclitaxel + gemcitabine (8.5 months), differences in sample sizes and study populations notwithstanding \[[18](#onco12293-bib-0018){ref-type="ref"}\].

These encouraging phase I results supported further clinical investigation in part B of this two‐part study; however, the phase II portion of the trial was discontinued following a planned interim futility analysis, which did not show a sufficient level of efficacy to warrant continuation of study accrual. The phase II results will be reported separately.

Trial Information {#onco12293-sec-0006}
=================

DiseasePancreatic cancerStage of Disease/TreatmentMetastatic/advancedPrior TherapyNoneType of Study -- 1Phase IType of Study -- 23 + 3Primary EndpointSafetyPrimary EndpointTolerabilitySecondary EndpoinMTDSecondary EndpointRecommended phase II doseSecondary EndpointPKSecondary EndpointPD**Additional Details of Endpoints or Study Design** This was a phase I, open‐label, multiple ascending‐dose study of necuparanib given as monotherapy and then in combination with nab*‐*paclitaxel and gemcitabine for patients with newly diagnosed untreated metastatic pancreas adenocarcinoma. Following completion of the first two cohorts (0.5 and 1.0 mg/kg necuparanib + gemcitabine), a protocol amendment in 2013 added nab‐paclitaxel to the regimen following the presentation of MPACT study results supporting the combination. Dose escalation was conducted via a modified 3 + 3 design and occurred if all patients in the studied cohort completed cycle 1 without a dose‐limiting toxicity (DLT). If a DLT was observed in one patient in the initial cohort of three to four patients, the cohort was expanded to six or seven patients. Dose escalation continued until the maximum tolerated dose (MTD) was defined. The protocol was modified during cohort 6 dosing to specify a maximum necuparanib dose of 450 mg (maximum of two injections of 225 mg/1.5 mL for each injection) following indications that daily doses greater than this were associated with elevated coagulation parameters. Dose escalation was to be terminated if two patients in the same cohort experienced a DLT in cycle 1. A DLT was defined as any AE judged by the investigator to be drug‐related and assessed as grade ≥3 according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Safety data in patients who received at least one dose of at least one of the study drugs were summarized by treatment group, and descriptive statistics were calculated for quantitative data and differences from baseline, as appropriate. Pharmacokinetic and PD parameters were calculated using noncompartmental methods and summarized by treatment group using descriptive statistics. Investigator\'s AnalysisActivity and safety demonstrated. Proceeded to randomized phase II, but futility met in phase II

Drug Information for Phase I Control {#onco12293-sec-0007}
====================================

Drug 1 Generic/Working nameNecuparanibCompany nameMomenta PharmaceuticalsDrug typeBiologicalDrug classOther: heparan sulfate mimeticDose0.5--5 milligrams (mg) per kilogram (kg)RouteOther: subcutaneousSchedule of administrationDaily subcutaneous doses in cohorts from 0.5 to 5 mg/kg; dose capped at 450 mgDrug 2 Generic/Working nameNab‐paclitaxelTrade nameAbraxaneCompany nameCelgeneDrug typeSmall moleculeDrug classTubulin/Microtubules targeting agentDose125 mg/m^2^RouteIVSchedule of administrationDays 1, 8, and 15 of a 28‐day cycleDrug 3 Generic/Working nameGemcitabineTrade nameGemzarCompany nameEli LillyDrug typeSmall moleculeDrug classAntimetaboliteDose1,000 mg/m^2^RouteIVSchedule of administrationDays 1, 8, and 15 of a 28‐day cycleDrug 4 Generic/Working nameNew drugCompany nameMomenta PharmaceuticalsDrug typeBiologicalDrug classOtherDose0.5 mg/kgRouteSubcutaneous

Patient Characteristics for Phase I Control {#onco12293-sec-0008}
===========================================

Number of Patients, Male12Number of Patients, Female27StageIV pancreas adenocarcinomaAgeMedian (range): 63 yearsNumber of Prior Systemic TherapiesMedian (range): 0Performance Status: ECOG0 --- 211 --- 182 ---3 ---Unknown ---

Primary Assessment Method for Phase I Control {#onco12293-sec-0009}
=============================================

TitleNecuparanib, nab‐paclitaxel, gemcitabine (*n* = 24)Number of Patients Enrolled39Number of Patients Evaluable for Toxicity39Number of Patients Evaluated for Efficacy24Evaluation MethodRECIST 1.1Response Assessment CR*n* = 0 (0%)Response Assessment PR*n* = 9 (38%)Response Assessment SD*n* = 6 (25%)Response Assessment PD*n* = 2 (8%)(Median) Duration Assessments PFS5.9 months, CI: 2.1--8.7(Median) Duration Assessments OS13.1 months, CI: 4.0--16.6

Phase I Control Adverse Events {#onco12293-sec-0010}
==============================

imageJohn Wiley & Sons, Ltd.[^1][^2]

Dose‐Limiting Toxicities Table {#onco12293-sec-0011}
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Assessment, Analysis, and Discussion {#onco12293-sec-0012}
====================================

CompletionStudy completedInvestigator\'s AssessmentActivity and safety demonstrated. Proceeded to randomized phase II, but futility met in phase II
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This was the first clinical evaluation of necuparanib, a novel therapeutic agent, which was conducted in patients with metastatic pancreatic adenocarcinoma. Necuparanib in combination with nab‐paclitaxel and gemcitabine demonstrated acceptable tolerability. No clear dose‐proportional trends in individual adverse events (AEs) were observed. The most common AEs had comparable rates, when necuparanib was administered with gemcitabine with or without nab‐paclitaxel, to what would be expected with chemotherapy alone. With the exception of anemia, the grade 3/4 hematological toxicities observed in this study in the necuparanib + nab‐paclitaxel and gemcitabine cohort were similar to those observed in the Von Hoff et al. phase III study (neutropenia, 3% vs. 38%; anemia, 3% vs. 13%; and thrombocytopenia, 0% vs. 13%, respectively). No grade 3/4 AEs of leukocytosis, febrile neutropenia, epistaxis, pulmonary embolism, deep vein thrombosis, phlebitis, or hematuria were reported with the necuparanib + nab‐paclitaxel and gemcitabine regimen.

Based on collective safety and on pharmacokinetic, progressive disease, biomarker, and efficacy data, a 5 mg/kg necuparanib dose, with capping at 450 mg, providing for a reasonable injection volume (i.e., two injections daily), was selected for further clinical evaluation in part B. Progressive disease data (i.e., hepatocyte growth factor) showed saturation with necuparanib 5 mg/kg and subtherapeutic levels of anticoagulation, which may be beneficial for thrombosis prevention. Promising antitumor activity was observed, as evidenced by survival and response data, with an overall disease‐control rate of 63% when all dose cohorts were pooled. Similarly, promising effects on reduction in CA19.9 levels from baseline with necuparanib treatment were observed. The median OS for patients who received at least one dose (13.1 months) and at least one cycle (15.6 months) of necuparanib + nab*‐*paclitaxel + gemcitabine compared favorably with the phase III data for nab*‐*paclitaxel + gemcitabine (8.5 months), differences in sample sizes and study populations notwithstanding.

These encouraging phase I results supported further clinical investigation in part B of this two‐part study; however, the phase II portion of the trial was discontinued following a planned interim futility analysis, which did not show a sufficient level of efficacy to warrant continuation of study accrual. The phase II results will be documented in a separate publication.

Figures and Tables {#onco12293-sec-1017}
==================

![Dose escalation and disposition in patients receiving at least one dose of necuparanib.\
Abbreviations: aPTT, activated partial thromboplastin time; DLT, dose‐limiting toxicity; Gem, gemcitabine; HGF, hepatocyte growth factor; LFTs, liver function tests; NabP, nab‐paclitaxel; Necu, necuparanib; PK, pharmacokinetics.](onco12293-fig-0001){#onco12293-fig-0001}

![Concentration of necuparanib for patients with at least three measurable levels on day 1.](onco12293-fig-0002){#onco12293-fig-0002}

![Activated partial thromboplastin time and prothrombin time in patients who received necuparanib in combination with nab‐paclitaxel and gemcitabine (cohorts 3--7).\
Abbreviations: aPTT, activated partial thromboplastin time; PT, prothrombin time.](onco12293-fig-0003){#onco12293-fig-0003}

![Mean (standard deviation) serum hepatocyte growth factor levels by dose group\
Abbreviations: Gem, gemcitabine; HGF, hepatocyte growth factor; NabP, nab‐paclitaxel; necu, necuparanib.](onco12293-fig-0004){#onco12293-fig-0004}

![Patient time on study for patients receiving necuparanib + gemcitabine (cohorts 1 and 2; **A**) or necuparanib + nab‐paclitaxel + gemcitabine (cohorts 3--7; **B**).\
Abbreviations: Gem, gemcitabine; NabP, nab‐paclitaxel; NE, not evaluable; Necu, necuparanib; PD, progressive disease; PR, partial response; SD, stable disease.](onco12293-fig-0005){#onco12293-fig-0005}

![Patient time on study for patients receiving necuparanib + gemcitabine (cohorts 1 and 2; **A**) or necuparanib + nab‐paclitaxel + gemcitabine (cohorts 3--7; **B**).\
Abbreviations: Gem, gemcitabine; NabP, nab‐paclitaxel; NE, not evaluable; Necu, necuparanib; PD, progressive disease; PR, partial response; SD, stable disease.](onco12293-fig-0006){#onco12293-fig-0006}

###### Baseline patient and disease characteristics

![](onco12293-tbl-0005){#nlm-graphic-33}

Data were available for the following numbers of patients (necuparanib + gemcitabine, necuparanib + nab‐paclitaxel + gemcitabine): ECOG (11, 24); tumor location and number of metastatic sites (12, 23); CA19.9 (9, 27).

^a^Not available for three patients.

Abbreviations: BMI, body mass index; CA, cancer antigen; ECOG, Eastern Cooperative Oncology Group.

###### Summary of adverse events

![](onco12293-tbl-0006){#nlm-graphic-35}

*n* (%) patients are shown. Adverse events have been sorted by necuparanib + gemcitabine + nab‐paclitaxel (cohort 3--7 total) results.

Abbreviations: ---, no adverse event; ↑, increased; AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Co, cohort;

###### Efficacy outcomes

![](onco12293-tbl-0007){#nlm-graphic-37}

Abbreviations: CI, confidence interval; CR, complete response; mo, Month; NE, not evaluable; PD, progressive disease; PFS, progression‐free survival; PR, partial response; OS, overall survival; RECIST, Response Evaluation Criteria In Solid Tumors; SD, Stable disease.
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See the related commentary on page [1424](10.1634/theoncologist.2017-0453).
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[^1]: *n* (%) patients are shown. Adverse events have been sorted by necuparanib + gemcitabine + nab‐paclitaxel (cohort 3--7 total) results.

[^2]: Abbreviations: ---, no adverse event; ↑, increased; AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Co, cohort.

[^3]: Abbreviations: aPTT, activated partial thromboplastin time; LFT, liver function test.
